ObsEva SA - Company Profile

Powered by

All the data and insights you need on ObsEva SA in one report.

$ $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date ObsEva SA Strategy Report

  • Understand ObsEva SA position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

ObsEva SA: Overview

Select Item

ObsEva SA (ObsEva) is a clinical-stage biopharmaceutical company that develops and commercializes drugs for women’s reproductive health and pregnancy. The company's product portfolio comprises pipeline products for controlling preterm labor by reducing inflammation, decreasing uterine contractions, and preventing cervical changes and membrane ruptures; for the treatment of pain in association with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women and to decrease contractions, improve uterine blood flow and enhance the receptivity of the endometrium to the embryo implantation. ObsEva is headquartered in Geneva, Switzerland.

 Gain a 360-degree view of ObsEva SA and make more informed decisions for your business Gain a 360-degree view of ObsEva SA and make more informed decisions for your business Find out more
Headquarters Switzerland
Address Chemin Des Aulx 12, Plan-Les-Ouates, 1228
Website www.obseva.com
Telephone 41 22 5521558
No of Employees 15
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange OBSN (SWF)
Revenue (2021) $19.6M -11.5% (2021 vs 2020)
EPS XYZ
Net Income (2021) XYZ 43.6% (2021 vs 2020)
Market Cap* $620,000
Net Profit Margin (2021) XYZ 36.2% (2021 vs 2020)
* As of and is in US$
View ObsEva SA financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

ObsEva SA premium industry data and analytics

30+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for ObsEva SA’s relevant decision makers and contact details.

20+

Catalyst Calendar

Proactively evaluate ObsEva SA’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

20+

Clinical Trials

Determine ObsEva SA go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

10+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

3

Pipeline Drugs

Identify which of ObsEva SA’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

1

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Marketed Drugs

Understand ObsEva SA’s commercialized product portfolio to stay one step ahead of the market.

Products and Services

Products
Pipeline Products
Nolasiban :
IVF
XYZ
XYZ
XYZ
Understand ObsEva SA portfolio and identify potential areas for collaboration Understand ObsEva SA portfolio and identify potential areas for collaboration Find out more
Image for loader

Competitor Comparison

Key Parameters ObsEva SA Myovant Sciences Inc Ferring Holding SA Stragen Pharma SA
Headquarters Switzerland United States of America Switzerland Switzerland
City Plan-Les-Ouates Brisbane St-Prex Geneva
State/Province - California - Genf
No. of Employees 15 - - 150
Entity Type Public Private Private Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Annette Clancy Chairman Executive Board 2022 -
Fabien de Ladonchamps Chief Executive Officer Senior Management 2023 -
Will Brown Chief Financial Officer Senior Management 2022 -
Katja Buhrer Chief Strategy Officer Senior Management 2022 -
Jean-Pierre Gotteland, Ph.D. Chief Scientific Officer; Head - R&D Senior Management 2015 -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into ObsEva SA key executives to enhance your sales strategy Gain insight into ObsEva SA key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward